Sprint Bioscience AB (SPRINT) AI Stock Analysis

• Market Cap: €47.48M
• Dividend Yield: N/A
• Average Volume (3M): 251.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.24
• Revenue Growth: 30.02%
• EPS Growth: -3985.71%
• Country: SE
• Employees: 38
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 105,515,540
• 10 Day Avg. Volume: 158,583
• 30 Day Avg. Volume: 251,755
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.83
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

Sprint Bioscience's overall stock score is low, primarily due to financial challenges such as negative profitability and cash flows, bearish technical indicators, and unattractive valuation metrics. The lack of debt is a positive, but the company needs to improve revenue stability and cost efficiency to enhance its financial health.

Sprint Bioscience AB Business Overview & Revenue Model

Company Description

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.

How the Company Makes Money

Sprint Bioscience generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical companies. By advancing its drug candidates to a preclinical stage, the company positions itself to enter partnerships where it grants rights to its drug candidates in exchange for upfront payments, milestone payments, and royalties on future sales. These partnerships allow Sprint Bioscience to leverage the resources and expertise of established pharma companies to bring its innovations to market. Additionally, the company may receive government grants or research funding to support its development projects, although these are not its primary revenue streams.

Sprint Bioscience AB Financial Statement Overview

Summary

Sprint Bioscience faces typical financial challenges in the biotechnology sector, with volatile revenues and negative profitability metrics. Despite maintaining a debt-free position, negative cash flows and profitability are significant concerns that need addressing.

Income Statement

Sprint Bioscience has demonstrated inconsistent revenue growth, with a notable jump from 2022 to 2023, but profitability remains a concern due to persistent negative EBIT and net income margins. The company struggles with generating consistent gross profits, indicating cost management issues.

Balance Sheet

The balance sheet reflects significant reliance on equity financing with no debt, which is positive for financial stability. However, the return on equity remains negative due to continuing net losses. Despite a small equity base, the absence of debt limits financial risk.

Cash Flow

Cash flows are volatile, with a shift from positive to negative operating cash flow in recent years. Free cash flow has been consistently negative, reflecting challenges in generating sufficient cash from operations to cover capital expenditures.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
65.64M	50.48M	83.00K	35.11M	16.89M
	Gross Profit
37.30M	41.79M	-60.91M	24.68M	6.43M
	EBIT
-19.67M	-845.00K	-60.91M	-25.47M	-37.67M
	EBITDA
-17.32M	-2.08M	-60.00M	-24.49M	-38.05M
	Net Income Common Stockholders
-18.28M	-438.00K	-60.17M	-25.35M	-46.23M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
25.06M	49.93M	29.49M	70.64M	27.07M
	Total Assets
42.05M	62.38M	37.42M	79.14M	33.40M
	Total Debt
0.00	0.00	0.00	0.00	10.00M
	Net Debt
-25.06M	-49.93M	-29.49M	-70.64M	-17.07M
	Total Liabilities
32.78M	34.60M	9.23M	8.68M	24.25M
	Stockholders Equity
9.27M	27.77M	28.19M	70.45M	9.14M
Cash Flow		Free Cash Flow
-24.65M	20.42M	-59.05M	-42.82M	-32.22M
	Operating Cash Flow
-23.36M	22.87M	-59.05M	-40.12M	-32.22M
	Investing Cash Flow
-1.30M	-2.45M	0.00	-2.71M	0.00
	Financing Cash Flow
-225.00K	24.00K	17.90M	86.39M	50.92M

Sprint Bioscience AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPRINT, the sentiment is Neutral. The current price of 0.44 is above the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.56, and below the 200-day MA of 1.25, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 40.76 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SPRINT.

Sprint Bioscience AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
SPRINT	39 Underperform	€47.48M	―	-147.64%	―	30.02%	-3985.71%
4K4		€2.39M	―	-105.54%	―	―	―
99Z		€4.56M	―	-222.24%	―	―	―
5JD0		€5.42M	―	-66.45%	―	―	―
7UX		€6.72M	―	-105.78%	―	―	―
COJ0		€4.31M	―	-47.01%	―	―	―